K. Patro, A. Avinash, Arya Banidutta, C. Kundu, Partha Sarathi Bhattacharya, V. Pilaka, Mrutyunjayarao Muvvala, AyyalasomayajulaAnil Kumar, Srinu Aketi, Keerthiga Karthikeyan, Bhargava Krishna Madasu, Dona Treesa Vincent
eyelid carcinoma
眼睑癌
{"title":"Implementing high-dose rate surface mould brachytherapy for carcinoma of eyelid: a practical approach and weekly review","authors":"K. Patro, A. Avinash, Arya Banidutta, C. Kundu, Partha Sarathi Bhattacharya, V. Pilaka, Mrutyunjayarao Muvvala, AyyalasomayajulaAnil Kumar, Srinu Aketi, Keerthiga Karthikeyan, Bhargava Krishna Madasu, Dona Treesa Vincent","doi":"10.3857/roj.2023.00682","DOIUrl":"https://doi.org/10.3857/roj.2023.00682","url":null,"abstract":"eyelid carcinoma","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Debnarayan Dutta, Meenu Jose, S. Kalavagunta, A. Sasidharan, Haridas Nair, A. Edappattu
Hypo-RT, and UF-RT cohort was 18.8 months (range, 2.4 to 76.8); 6.6 months (range, 2 to 17.4), and 13.9 months (range, 3 to 131.9). Median OS as per Combs criteria were 16.6 months (Group a), 24.6 months (Group b), 4.6 months (Group c), and 3 months (Group d). Significant survival benefit was with good KPS score (KPS >80 vs. <80; 20.46 vs. 5.25 months; p < 0.001), patients receiving salvage chemotherapy (20.46 vs. 6.96 months; p = 0.001), and patients received re-RT biological equivalent dose (BED 3 ) >80 Gy (16.62 vs. 5.48 months; p = 0.03). Median overall survival (OS) in our patient cohort and Combs cohort in Group a was 16.6 and 19.5 months; Group b was 24.6 and 11.3 months; Group c was 4.7 and 8.1 months, and Group d was 2 and 5.5 months, respectively. Six months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 100%, 92%, 34%, 17% and 94%, 79%, 70%, 41%, respectively. Twelve months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 88%, 74%, 22%, 0% and 88%, 47%, 22%, 7%, respectively. Conclusion: Modified Combs prognostic factors predicts OS and is applicable in Indian subcontinent patient population.
{"title":"Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation","authors":"Debnarayan Dutta, Meenu Jose, S. Kalavagunta, A. Sasidharan, Haridas Nair, A. Edappattu","doi":"10.3857/roj.2023.00542","DOIUrl":"https://doi.org/10.3857/roj.2023.00542","url":null,"abstract":"Hypo-RT, and UF-RT cohort was 18.8 months (range, 2.4 to 76.8); 6.6 months (range, 2 to 17.4), and 13.9 months (range, 3 to 131.9). Median OS as per Combs criteria were 16.6 months (Group a), 24.6 months (Group b), 4.6 months (Group c), and 3 months (Group d). Significant survival benefit was with good KPS score (KPS >80 vs. <80; 20.46 vs. 5.25 months; p < 0.001), patients receiving salvage chemotherapy (20.46 vs. 6.96 months; p = 0.001), and patients received re-RT biological equivalent dose (BED 3 ) >80 Gy (16.62 vs. 5.48 months; p = 0.03). Median overall survival (OS) in our patient cohort and Combs cohort in Group a was 16.6 and 19.5 months; Group b was 24.6 and 11.3 months; Group c was 4.7 and 8.1 months, and Group d was 2 and 5.5 months, respectively. Six months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 100%, 92%, 34%, 17% and 94%, 79%, 70%, 41%, respectively. Twelve months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 88%, 74%, 22%, 0% and 88%, 47%, 22%, 7%, respectively. Conclusion: Modified Combs prognostic factors predicts OS and is applicable in Indian subcontinent patient population.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139605179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
hypo-thyroidism (1.50; 95% CI, 1.1–2.1) were significantly increased after TBI. However, there were no significant differences in the occurrence of myocardial infarction and stroke according to TBI. Conclusions: Our results suggest that modern TBI may not additionally increase the risk of SC after allogeneic HSCT, although increased risks of other diseases were noted. Physicians should carefully consider individualized risks and benefits of TBI, with a particular focus by age group.
{"title":"Long-term toxicities after allogeneic hematopoietic stem cell transplantation with or without total body irradiation: a population-based study in Korea","authors":"J. Kwon, Byoung Hyuck Kim","doi":"10.3857/roj.2023.00871","DOIUrl":"https://doi.org/10.3857/roj.2023.00871","url":null,"abstract":"hypo-thyroidism (1.50; 95% CI, 1.1–2.1) were significantly increased after TBI. However, there were no significant differences in the occurrence of myocardial infarction and stroke according to TBI. Conclusions: Our results suggest that modern TBI may not additionally increase the risk of SC after allogeneic HSCT, although increased risks of other diseases were noted. Physicians should carefully consider individualized risks and benefits of TBI, with a particular focus by age group.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139618556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Novikov, Petr Krivorotko, Zhanna Bryantseva, I. Akulova, A. Emelyanov, V. Mortada, Olga Ponomareva, P. Krzhivitskiy, Sergey Kanaev
Purpose: We evaluate various approaches to target volume definition and boost delivery in patients with complete response to neoadjuvant systemic therapy (NST) who were treated by radiotherapy without a surgery. Materials and Methods: A pathological complete response (pCR) was diagnosed in 21 of 27 patients included in “surgery de-escalation” prospective observation study. Clips were placed in the primary tumor volume (PrTV) before NST and during the vacuum aspiration biopsy. Twenty patients with pCR underwent the whole breast irradiation and a boost to the PrTV. High-dose rate brachytherapy (HDRB) was the basic technique for boost delivery. Finally, we identified the value of fused images (computed tomography [CT] before NST with simulation CT), clips and their combination for an accurate boost delivery.Results: A complete overlap between PrTV on pre-treatment CT with the localization of the clips on simulation CT was mentioned in 10, partial mismatch in three patients. In 12 of these 13 women, HDRB was successfully used for the boost delivery. In five cases we mentioned a marked discrepancy between the PrTV on fused images and the topography of the clips. In other two women we did not find clips on simulation CT. The fused images in five of these seven patients showed anatomical landmarks (scar, fibrosis) used for identification of the gross tumor volume. In all 20 women with pCR (average follow-up of 16.6 months), there were no locoregional recurrences.Conclusion: Combination of the clips with fusion of pre-NST and simulation CTs is important for an accurate boost delivery.
{"title":"Different approaches to target volume definition and boost delivery in surgery de-escalation clinical trial in breast cancer patients with pathological complete response","authors":"S. Novikov, Petr Krivorotko, Zhanna Bryantseva, I. Akulova, A. Emelyanov, V. Mortada, Olga Ponomareva, P. Krzhivitskiy, Sergey Kanaev","doi":"10.3857/roj.2023.00528","DOIUrl":"https://doi.org/10.3857/roj.2023.00528","url":null,"abstract":"Purpose: We evaluate various approaches to target volume definition and boost delivery in patients with complete response to neoadjuvant systemic therapy (NST) who were treated by radiotherapy without a surgery. Materials and Methods: A pathological complete response (pCR) was diagnosed in 21 of 27 patients included in “surgery de-escalation” prospective observation study. Clips were placed in the primary tumor volume (PrTV) before NST and during the vacuum aspiration biopsy. Twenty patients with pCR underwent the whole breast irradiation and a boost to the PrTV. High-dose rate brachytherapy (HDRB) was the basic technique for boost delivery. Finally, we identified the value of fused images (computed tomography [CT] before NST with simulation CT), clips and their combination for an accurate boost delivery.Results: A complete overlap between PrTV on pre-treatment CT with the localization of the clips on simulation CT was mentioned in 10, partial mismatch in three patients. In 12 of these 13 women, HDRB was successfully used for the boost delivery. In five cases we mentioned a marked discrepancy between the PrTV on fused images and the topography of the clips. In other two women we did not find clips on simulation CT. The fused images in five of these seven patients showed anatomical landmarks (scar, fibrosis) used for identification of the gross tumor volume. In all 20 women with pCR (average follow-up of 16.6 months), there were no locoregional recurrences.Conclusion: Combination of the clips with fusion of pre-NST and simulation CTs is important for an accurate boost delivery.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139135845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Radiotherapy (RT) is the main local treatment for limited-stage small-cell lung cancer (LS-SCLC). No-tably, SCLC is extremely sensitive to radiotherapy. Turrisi et al. [1] demonstrated the oncological benefit of high radiation doses by showing the survival benefit of a 45 Gy/1.5 Gy bid protocol compared to the conventional 45 Gy in 25 fractions treatment. Recently, Faivre-Finn et al. [2] reported that treatment with 66 Gy in 33 fractions could achieve a survival similar to that of the bid regimen. Ref-erencing the literature on non-small cell lung cancer (NSCLC), dose-escalation beyond 60–66 Gy is not always successful and has the potential to increase toxicity [3
{"title":"Proton beam therapy as a promising option for high-risk limited stage small cell lung cancer: revealing potential of future novel agents","authors":"C. H. Rim","doi":"10.3857/roj.2023.01004","DOIUrl":"https://doi.org/10.3857/roj.2023.01004","url":null,"abstract":"Radiotherapy (RT) is the main local treatment for limited-stage small-cell lung cancer (LS-SCLC). No-tably, SCLC is extremely sensitive to radiotherapy. Turrisi et al. [1] demonstrated the oncological benefit of high radiation doses by showing the survival benefit of a 45 Gy/1.5 Gy bid protocol compared to the conventional 45 Gy in 25 fractions treatment. Recently, Faivre-Finn et al. [2] reported that treatment with 66 Gy in 33 fractions could achieve a survival similar to that of the bid regimen. Ref-erencing the literature on non-small cell lung cancer (NSCLC), dose-escalation beyond 60–66 Gy is not always successful and has the potential to increase toxicity [3","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139135630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Choi, B. Jeong, Hojin Jeong, I. Ha, Bong-Hoi Choi, K. Kang
mm for neck LN level II, 5 mm for neck LN level III, and 3 mm for neck LN level IV was required to include all movements of each LN level. In patients using bite block, changes in primary tumor volume, and metastatic LN volume were related to significant movement.
颈部 LN 水平 II 需要 5 毫米，颈部 LN 水平 III 需要 5 毫米，颈部 LN 水平 IV 需要 3 毫米，以包括每个 LN 水平的所有移动。在使用咬合阻滞的患者中，原发肿瘤体积和转移 LN 体积的变化与明显的移动有关。
{"title":"Target movement according to cervical lymph node level in head and neck cancer and its clinical significance","authors":"H. Choi, B. Jeong, Hojin Jeong, I. Ha, Bong-Hoi Choi, K. Kang","doi":"10.3857/roj.2023.00787","DOIUrl":"https://doi.org/10.3857/roj.2023.00787","url":null,"abstract":"mm for neck LN level II, 5 mm for neck LN level III, and 3 mm for neck LN level IV was required to include all movements of each LN level. In patients using bite block, changes in primary tumor volume, and metastatic LN volume were related to significant movement.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138957982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyunseok Lee, D. Oh, Y. Ahn, Hongryull Pyo, Kyungmi Yang, J. Noh
lower mean lung dose (4.4 Gy vs. 7.6 Gy vs. 10.9 Gy, respectively; p < 0.001), lower mean heart dose (5.4 Gy vs. 10.0 Gy vs. 13.1 Gy, respectively; p = 0.003), and lower mean esophageal dose than patients in the 3D-CRT and IMRT groups (6.3 Gy vs. 9.8 Gy vs. 13.5 Gy, respectively; p = 0.011). Twenty patients (19.8%) showed disease recurrence, and seven patients (6.9%) died. The differences in the survival rates between RT groups were not statistically significant. Conclusion: In patients with TET who underwent adjuvant RT, PBT resulted in a lower dose of exposure to adjacent organs at risk. Survival outcomes for patients in PBT group were not significantly different from those in other groups.
与 3D-CRT 组和 IMRT 组患者相比，3D-CRT 组患者的平均肺部剂量（分别为 4.4 Gy vs. 7.6 Gy vs. 10.9 Gy；p < 0.001）、平均心脏剂量（分别为 5.4 Gy vs. 10.0 Gy vs. 13.1 Gy；p = 0.003）和平均食管剂量（分别为 6.3 Gy vs. 9.8 Gy vs. 13.5 Gy；p = 0.011）更低。20名患者（19.8%）出现疾病复发，7名患者（6.9%）死亡。不同 RT 组的存活率差异无统计学意义。结论在接受辅助 RT 的 TET 患者中，PBT 对邻近危险器官的照射剂量较低。PBT组患者的存活率与其他组没有明显差异。
{"title":"Comparison of radiotherapy techniques in patients with thymic epithelial tumor who underwent postoperative radiotherapy","authors":"Hyunseok Lee, D. Oh, Y. Ahn, Hongryull Pyo, Kyungmi Yang, J. Noh","doi":"10.3857/roj.2023.00360","DOIUrl":"https://doi.org/10.3857/roj.2023.00360","url":null,"abstract":"lower mean lung dose (4.4 Gy vs. 7.6 Gy vs. 10.9 Gy, respectively; p < 0.001), lower mean heart dose (5.4 Gy vs. 10.0 Gy vs. 13.1 Gy, respectively; p = 0.003), and lower mean esophageal dose than patients in the 3D-CRT and IMRT groups (6.3 Gy vs. 9.8 Gy vs. 13.5 Gy, respectively; p = 0.011). Twenty patients (19.8%) showed disease recurrence, and seven patients (6.9%) died. The differences in the survival rates between RT groups were not statistically significant. Conclusion: In patients with TET who underwent adjuvant RT, PBT resulted in a lower dose of exposure to adjacent organs at risk. Survival outcomes for patients in PBT group were not significantly different from those in other groups.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sang Hoon Seo, Hongryull Pyo, Yong Chan Ahn, D. Oh, Kyungmi Yang, Nalee Kim, Jong-Mu Sun, Sehhoon Park, H. Jung, Se-Hoon Lee, J. Ahn, Myung-Ju Ahn, J. Noh
and radiation-related toxicities in LS-SCLC. PBT may be a valuable therapeutic modality in patients with poor pulmonary function or extensive disease burden owing to its lung-sparing ability.
{"title":"Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer","authors":"Sang Hoon Seo, Hongryull Pyo, Yong Chan Ahn, D. Oh, Kyungmi Yang, Nalee Kim, Jong-Mu Sun, Sehhoon Park, H. Jung, Se-Hoon Lee, J. Ahn, Myung-Ju Ahn, J. Noh","doi":"10.3857/roj.2023.00773","DOIUrl":"https://doi.org/10.3857/roj.2023.00773","url":null,"abstract":"and radiation-related toxicities in LS-SCLC. PBT may be a valuable therapeutic modality in patients with poor pulmonary function or extensive disease burden owing to its lung-sparing ability.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138596485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CyberKnife-based stereotactic radiosurgery or fractionated stereotactic radiotherapy in older patients with brain metastases from non-small cell lung cancer","authors":"Jeongshim Lee, H. Kim, Woo Chul Kim","doi":"10.3857/roj.2023.00563","DOIUrl":"https://doi.org/10.3857/roj.2023.00563","url":null,"abstract":"clinical results of CyberKnife","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139224037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：